This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Toner, L. E. Articles by O'Connor, O. A. Search for Related Content PubMed PubMed Citation Articles by Toner, L. E. Articles by O'Connor, O. A.

The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma

Authors' Affiliations: Laboratories of ¹ Experimental Therapeutics for the Lymphoproliferative Malignancies and ² Molecular and Cellular Hematology; ³ Leukemia, ⁴ Lymphoma, and ⁵ Developmental Chemotherapy Services, Division of Hematological Oncology, Department of Medicine; Departments of ⁶ Biostatistics and ⁷ Pathology; and ⁸ Molecular Pharmacology and Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York

Requests for reprints: Owen A. O'Connor, Department of Medicine, Memorial Sloan Kettering Cancer Center, Box 329, 1275 York Avenue, New York, NY 10021. Phone: 212-639-8889; Fax: 212-639-2767; E-mail: oconnoro{at}mskcc.org.

Purpose: Methotrexate is known to synergize with cytarabine [1-ß-D-arabinofuranosylcytosine (ara-C)] in a schedule-dependent manner. The purpose of this article is to compare and contrast the activity of pralatrexate (10-propargyl-10-deazaminopterin)/gemcitabine to the standard combination of methotrexate/ara-C and to determine if schedule dependency of this combination is important in lymphoma.

Experiment Design: Cytotoxicity assays using the standard trypan blue exclusion assay were used to explore the in vitro activity of pralatrexate and gemcitabine against a panel of lymphoma cell lines. Both severe combined imunodeficient beige and irradiated nonobese diabetic/severe combined imunodeficient mouse xenograft models were used to compare and contrast the in vivo activity of these combinations as a function of schedule. In addition, apoptosis assays were conducted.

Results: Compared with methotrexate-containing combinations, pralatrexate plus gemcitabine combinations displayed improved therapeutic activity with some schedule dependency. The combination of pralatrexate and gemcitabine was superior to any methotrexate and ara-C combination in inducing apoptosis and in activating caspase-3. In vivo, the best therapeutic effects were obtained with the sequence of pralatrexate gemcitabine. Complete remissions were only appreciated in animals receiving pralatrexate followed by gemcitabine.

Conclusions: These data show that the combination of pralatrexate followed by gemcitabine was superior to methotrexate/ara-C in vitro and in vivo, and was far more potent in inducing apoptosis in a large B-cell lymphoma. These data provide strong rationale for further study of this combination in lymphomas where methotrexate and ara-C are used.